

# PRODUCT DATA SHEET

## ANTI-HUMAN CLAUDIN 9 MONOCLONAL ANTIBODY


### PRODUCT INFORMATION

<b>Catalog Number:</b>	GM-1111	<b>Clone:</b>	YD-4E9
<b>Description:</b>	purified monoclonal rat antibody	<b>Specificity:</b>	anti-human Claudin 9
<b>Isotype:</b>	IgG2b	<b>Purification:</b>	Protein G
<b>Storage:</b>	short term: 2°C – 8°C; long term: –20°C (avoid repeated freezing and thawing)	<b>Buffer:</b>	phosphate buffered saline, pH 7.2
<b>Immunogen:</b>	genetic immunization with cDNA encoding human Claudin 9	<b>Selection:</b>	based on recognition of the complete native protein expressed on transfected mammalian cells

### WORKING DILUTIONS

<b>Flow cytometry:</b>	1.2 µg/10 <sup>6</sup> cells		
<b>ELISA:</b>	1:200 – 1:400	<b>CELISA:</b>	1:200 – 1:400
For each application a titration should be performed to determine the optimal concentration.			

### SPECIFICITY TESTING BY FLOW CYTOMETRY



**Fig.1:** GM-1111. BOSC23 cells were transiently transfected with an expression vector encoding either Claudin 9 (red curve) or an irrelevant protein (control transfectant). Binding of YD-4E9 was detected with a PE conjugated secondary antibody. A positive signal was obtained only with Claudin 9 transfected cells.

CONFIDENTIAL

Genovac GmbH

Waltershofener Str. 17

79111 Freiburg im Breisgau, Germany

catalogue@genovac.com

www.genovac.com


For research use only. Not for diagnostic or therapeutic use.

For licensing information, please contact us at [licensing@genovac.com](mailto:licensing@genovac.com)

Page 1 / 2

## SDS PAGE ANALYSIS OF YD-4E9

The antibody was purified by protein G affinity chromatography from cell culture supernatants and verified by SDS-page (Fig. 2).



**Fig. 2:** SDS-PAGE analysis of purified YD-4E9 monoclonal antibody. Lane 1: molecular weight marker, Lane 2: 2 µg of purified YD-4E9 antibody. Proteins were separated by SDS-PAGE and stained with RAPID Stain™ Reagent.

## BACKGROUND

Claudin 9 belongs to the claudin family which constitutes a large group of four-transmembrane domain proteins (1). Claudins are integral tight junction proteins that are responsible for maintaining the integrity of epithelial cell architecture, the control of paracellular transport and cell polarity. The expression pattern of claudins is tissue specific, most tissues express multiple claudins, which can interact in both homotypic and heterotypic fashion to form the tight junction strands (2). Several claudin proteins have been shown to be abnormally expressed in cancers. The differential expression of these proteins between tumour and normal cells, in addition to their membrane localisation, makes them prime candidates for cancer therapy (2).

Members of the claudin family, including Claudin 6 and 9 are expressed in the liver and play a critical role in Hepatitis C Infection. They function as coreceptors in HCV entry and assume a role in HCV dissemination, replication and pathogenesis (3, 4).

## REFERENCES

1. **Kazumasa M, Mikio F, Kazushi F, Shoichiro T (1999).** Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. *Proc Natl Acad Sci U S A.* 19; 96(2): 511-516.
2. **Morin PJ (2005).** Claudin proteins in human cancer: promising new targets for diagnosis and therapy. *Cancer Res.* 1;65(21):9603-6.
3. **Zheng A, Yuan F, Li Y, Zhu F, Hou P, Li J, Song X, Ding M, Deng H (2007).** Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus. *J Virol.* 81(22):12465-71.
4. **Fofana I, Zona L, Thumann C, Heydmann L, Durand SC, Lupberger J, Blum HE, Pessaux P, Gondeau C, Reynolds GM, McKeating JA, Grunert F, Thompson J, Zeisel MB, Baumert TF (2013).** Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes by using monoclonal antibodies. *J Virol.* 87(18):10405-10

## CONFIDENTIAL

Genovac GmbH

Waltershofener Str. 17  
79111 Freiburg im Breisgau, Germany

catalogue@genovac.com  
www.genovac.com

For research use only. Not for diagnostic or therapeutic use.  
For licensing information, please contact us at licensing@genovac.com